Effect of Biodegradable Mifepristone Drug Delivery System on the Ultrastructure and Angiogenesis Related Factors of Adenomyosis Cells

Jianhua Wang
In: Science of Advanced Materials · 2024 · vol. 16(2) , pp. 236–243 · doi:10.1166/sam.2024.4613 · W4392002415
article OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Biodegradable mifepristone nanoparticles reduced adenomyosis cell proliferation and angiogenesis markers while increasing apoptosis, suggesting improved treatment efficacy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The aim of this research aimed to analyze the effects of degradable mifepristone nano-drug delivery system (DDS) on the ultrastructure, proliferation, apoptosis, and angiogenesis of adenomyosis cells. Drug-loaded nanoparticles (DNPs) of poly lactic-co-glycolic acid (PLGA) were prepared. The particle size distribution and surface Zeta potential (SZP) of nanoparticles (NPs) were detected. The morphology of NPS was subjected to observation by transmission electron microscope (TEM). Adenomyosis lesion cells were cultured by tissue digestion method, and the cell morphology was observed and identified. The cells were divided into blank control (NC), mifepristone, and mifepristone/PLGA groups. The cell proliferation, ultrastructure, apoptosis, and the expression of Survivin, VEGFR1, and VEGFR2 were detected by MTT, TEM, flow cytometry (FC), and immuno-histochemistry, respectively. The results suggested that the average particle size of mifepristone/PLGA NPs was (185.6±12.9) nm, and the SZP was (−9.5±0.9) mV. It presented the characteristics of circularity, uniform distribution, and smooth surface under TEM. As against the raw drug mifepristone, the release time of mifepristone/PLGA NPs was prolonged, and the drug release rate reached 87.4% at 72 h. As against NC, the cell proliferation rate (CPR) was clearly decreased, the apoptosis rate (AR) was increased, and Survivin, VEGFR1, and VEGFR2 had a decrease in mifepristone and mifepristone/PLGA groups ( P <0.05). As against mifepristone group, the CPR was clearly decreased, the AR was increased, and Survivin, VEGFR1, and VEGFR2 had a decrease in mifepristone/PLGA group ( P <0.05). In conclusion, mifepristone PLGA DNPs were able to delay drug release. Mifepristone can inhibit angiogenesis and promote apoptosis of adenomyosis by affecting the expression of Survivin, VEGFR1, and VEGFR2, thus playing a role in the treatment of adenomyosis.

My notes (saved in your browser only)

Condition tags

adenomyosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

References (36)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK